Lederman Seth's Form 4 filing
Tonix Pharmaceuticals Holding Corp. (TNXP) · filed Apr 1, 2026
- Accession no.
- 0001999371-26-007447
- Filed
- Apr 1, 2026
- Trade date
- Mar 31, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $63.1K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lederman SethCIK 0001563420 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Common Stock, $0.001 par value | PPurchaseAcquired | +5,000 | $12.62F1 | +$63,100 | 20,001 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $12.5699 to $12.625 per share. The Reporting Persons undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
Referenced by the price of 1 transaction in Table I.